1. Home
  2. STHO vs CRDL Comparison

STHO vs CRDL Comparison

Compare STHO & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STHO

Star Holdings Shares of Beneficial Interest

SELL

Current Price

$7.61

Market Cap

120.0M

Sector

Real Estate

ML Signal

SELL

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$0.97

Market Cap

123.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STHO
CRDL
Founded
2022
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.0M
123.9M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
STHO
CRDL
Price
$7.61
$0.97
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $8.41
AVG Volume (30 Days)
39.3K
★ 519.9K
Earning Date
11-06-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 24.73
N/A
EPS
N/A
★ N/A
Revenue
★ $110,143,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.25
$0.88
52 Week High
$9.94
$2.34

Technical Indicators

Market Signals
Indicator
STHO
CRDL
Relative Strength Index (RSI) 37.25 30.25
Support Level $7.36 $0.95
Resistance Level $9.10 $1.10
Average True Range (ATR) 0.29 0.07
MACD 0.05 0.01
Stochastic Oscillator 12.94 15.73

Price Performance

Historical Comparison
STHO
CRDL

About STHO Star Holdings Shares of Beneficial Interest

Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: